nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—Parkinson's disease—Memantine—Alzheimer's disease	0.25	0.5	CpDpCtD
L-DOPA—Parkinson's disease—Rivastigmine—Alzheimer's disease	0.25	0.5	CpDpCtD
L-DOPA—CYP2D6—Alzheimer's disease	0.124	1	CbGaD
L-DOPA—DRD2—Memantine—Alzheimer's disease	0.0758	0.453	CbGbCtD
L-DOPA—CYP2D6—Rivastigmine—Alzheimer's disease	0.0395	0.236	CbGbCtD
L-DOPA—CYP2D6—Donepezil—Alzheimer's disease	0.0316	0.189	CbGbCtD
L-DOPA—CYP2D6—Galantamine—Alzheimer's disease	0.0203	0.122	CbGbCtD
L-DOPA—DRD3—telencephalic ventricle—Alzheimer's disease	0.00392	0.0899	CbGeAlD
L-DOPA—DDC—telencephalic ventricle—Alzheimer's disease	0.00382	0.0876	CbGeAlD
L-DOPA—DRD1—telencephalic ventricle—Alzheimer's disease	0.00281	0.0644	CbGeAlD
L-DOPA—PSIP1—embryo—Alzheimer's disease	0.00198	0.0454	CbGeAlD
L-DOPA—PSIP1—forebrain—Alzheimer's disease	0.00175	0.0401	CbGeAlD
L-DOPA—DRD2—telencephalic ventricle—Alzheimer's disease	0.00166	0.038	CbGeAlD
L-DOPA—PSIP1—telencephalon—Alzheimer's disease	0.00161	0.0369	CbGeAlD
L-DOPA—SLC7A8—forebrain—Alzheimer's disease	0.00115	0.0265	CbGeAlD
L-DOPA—DDC—embryo—Alzheimer's disease	0.00113	0.0259	CbGeAlD
L-DOPA—SLC7A8—telencephalon—Alzheimer's disease	0.00106	0.0243	CbGeAlD
L-DOPA—DDC—forebrain—Alzheimer's disease	0.000997	0.0229	CbGeAlD
L-DOPA—DRD5—forebrain—Alzheimer's disease	0.000959	0.022	CbGeAlD
L-DOPA—PSIP1—nervous system—Alzheimer's disease	0.000949	0.0218	CbGeAlD
L-DOPA—DDC—telencephalon—Alzheimer's disease	0.000917	0.021	CbGeAlD
L-DOPA—PSIP1—central nervous system—Alzheimer's disease	0.000914	0.021	CbGeAlD
L-DOPA—Mimosine—CCL2—Alzheimer's disease	0.000912	0.273	CrCbGaD
L-DOPA—PSIP1—cerebellum—Alzheimer's disease	0.000893	0.0205	CbGeAlD
L-DOPA—DRD5—telencephalon—Alzheimer's disease	0.000882	0.0202	CbGeAlD
L-DOPA—SLC7A5—telencephalon—Alzheimer's disease	0.000821	0.0189	CbGeAlD
L-DOPA—DRD1—forebrain—Alzheimer's disease	0.000733	0.0168	CbGeAlD
L-DOPA—PSIP1—brain—Alzheimer's disease	0.000725	0.0167	CbGeAlD
L-DOPA—DRD1—telencephalon—Alzheimer's disease	0.000674	0.0155	CbGeAlD
L-DOPA—SLC7A8—nervous system—Alzheimer's disease	0.000625	0.0144	CbGeAlD
L-DOPA—DRD4—brain—Alzheimer's disease	0.000604	0.0139	CbGeAlD
L-DOPA—SLC7A8—central nervous system—Alzheimer's disease	0.000602	0.0138	CbGeAlD
L-DOPA—Masoprocol—IGF1R—Alzheimer's disease	0.000594	0.178	CrCbGaD
L-DOPA—Liothyronine—TTR—Alzheimer's disease	0.00059	0.176	CrCbGaD
L-DOPA—SLC7A8—cerebellum—Alzheimer's disease	0.000589	0.0135	CbGeAlD
L-DOPA—DRD3—nervous system—Alzheimer's disease	0.000555	0.0127	CbGeAlD
L-DOPA—DDC—nervous system—Alzheimer's disease	0.000541	0.0124	CbGeAlD
L-DOPA—DRD3—central nervous system—Alzheimer's disease	0.000535	0.0123	CbGeAlD
L-DOPA—DDC—central nervous system—Alzheimer's disease	0.000521	0.012	CbGeAlD
L-DOPA—DRD5—nervous system—Alzheimer's disease	0.00052	0.0119	CbGeAlD
L-DOPA—DRD5—central nervous system—Alzheimer's disease	0.000501	0.0115	CbGeAlD
L-DOPA—SLC7A5—nervous system—Alzheimer's disease	0.000485	0.0111	CbGeAlD
L-DOPA—SLC7A8—brain—Alzheimer's disease	0.000478	0.011	CbGeAlD
L-DOPA—SLC7A5—central nervous system—Alzheimer's disease	0.000467	0.0107	CbGeAlD
L-DOPA—SLC7A5—cerebellum—Alzheimer's disease	0.000456	0.0105	CbGeAlD
L-DOPA—DRD2—forebrain—Alzheimer's disease	0.000433	0.00994	CbGeAlD
L-DOPA—DRD3—brain—Alzheimer's disease	0.000424	0.00975	CbGeAlD
L-DOPA—DDC—brain—Alzheimer's disease	0.000414	0.0095	CbGeAlD
L-DOPA—DRD2—telencephalon—Alzheimer's disease	0.000398	0.00914	CbGeAlD
L-DOPA—DRD5—brain—Alzheimer's disease	0.000398	0.00913	CbGeAlD
L-DOPA—DRD1—nervous system—Alzheimer's disease	0.000398	0.00913	CbGeAlD
L-DOPA—DRD1—central nervous system—Alzheimer's disease	0.000383	0.00879	CbGeAlD
L-DOPA—SLC7A5—brain—Alzheimer's disease	0.000371	0.00851	CbGeAlD
L-DOPA—SLC16A10—cerebellum—Alzheimer's disease	0.000349	0.00802	CbGeAlD
L-DOPA—DRD1—brain—Alzheimer's disease	0.000304	0.00698	CbGeAlD
L-DOPA—CYP2D6—forebrain—Alzheimer's disease	0.00026	0.00597	CbGeAlD
L-DOPA—CYP2D6—telencephalon—Alzheimer's disease	0.000239	0.00549	CbGeAlD
L-DOPA—DRD2—nervous system—Alzheimer's disease	0.000235	0.00539	CbGeAlD
L-DOPA—Upper respiratory tract infection—Memantine—Alzheimer's disease	0.000234	0.00212	CcSEcCtD
L-DOPA—Tremor—Galantamine—Alzheimer's disease	0.000234	0.00212	CcSEcCtD
L-DOPA—Pollakiuria—Memantine—Alzheimer's disease	0.000233	0.00211	CcSEcCtD
L-DOPA—Ill-defined disorder—Galantamine—Alzheimer's disease	0.000232	0.0021	CcSEcCtD
L-DOPA—Anaemia—Galantamine—Alzheimer's disease	0.000231	0.00209	CcSEcCtD
L-DOPA—Weight increased—Memantine—Alzheimer's disease	0.000229	0.00208	CcSEcCtD
L-DOPA—Agitation—Galantamine—Alzheimer's disease	0.000229	0.00208	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Rivastigmine—Alzheimer's disease	0.000229	0.00208	CcSEcCtD
L-DOPA—Weight decreased—Memantine—Alzheimer's disease	0.000228	0.00207	CcSEcCtD
L-DOPA—Pollakiuria—Rivastigmine—Alzheimer's disease	0.000228	0.00206	CcSEcCtD
L-DOPA—DRD2—central nervous system—Alzheimer's disease	0.000226	0.00519	CbGeAlD
L-DOPA—Malaise—Galantamine—Alzheimer's disease	0.000225	0.00204	CcSEcCtD
L-DOPA—Weight increased—Rivastigmine—Alzheimer's disease	0.000224	0.00203	CcSEcCtD
L-DOPA—Depression—Memantine—Alzheimer's disease	0.000224	0.00203	CcSEcCtD
L-DOPA—Syncope—Galantamine—Alzheimer's disease	0.000224	0.00203	CcSEcCtD
L-DOPA—Haemoglobin—Donepezil—Alzheimer's disease	0.000223	0.00202	CcSEcCtD
L-DOPA—Weight decreased—Rivastigmine—Alzheimer's disease	0.000223	0.00202	CcSEcCtD
L-DOPA—Rhinitis—Donepezil—Alzheimer's disease	0.000223	0.00202	CcSEcCtD
L-DOPA—Haemorrhage—Donepezil—Alzheimer's disease	0.000222	0.00201	CcSEcCtD
L-DOPA—Acute coronary syndrome—Memantine—Alzheimer's disease	0.000222	0.00201	CcSEcCtD
L-DOPA—Hallucination—Donepezil—Alzheimer's disease	0.000221	0.002	CcSEcCtD
L-DOPA—Hypoaesthesia—Donepezil—Alzheimer's disease	0.000221	0.002	CcSEcCtD
L-DOPA—DRD2—cerebellum—Alzheimer's disease	0.000221	0.00508	CbGeAlD
L-DOPA—Palpitations—Galantamine—Alzheimer's disease	0.000221	0.002	CcSEcCtD
L-DOPA—Myocardial infarction—Memantine—Alzheimer's disease	0.00022	0.002	CcSEcCtD
L-DOPA—Neuropathy peripheral—Memantine—Alzheimer's disease	0.00022	0.002	CcSEcCtD
L-DOPA—Urinary tract disorder—Donepezil—Alzheimer's disease	0.00022	0.00199	CcSEcCtD
L-DOPA—Loss of consciousness—Galantamine—Alzheimer's disease	0.000219	0.00199	CcSEcCtD
L-DOPA—Depression—Rivastigmine—Alzheimer's disease	0.000219	0.00199	CcSEcCtD
L-DOPA—Urinary tract infection—Memantine—Alzheimer's disease	0.000219	0.00198	CcSEcCtD
L-DOPA—Urethral disorder—Donepezil—Alzheimer's disease	0.000218	0.00197	CcSEcCtD
L-DOPA—Cough—Galantamine—Alzheimer's disease	0.000218	0.00197	CcSEcCtD
L-DOPA—Acute coronary syndrome—Rivastigmine—Alzheimer's disease	0.000217	0.00196	CcSEcCtD
L-DOPA—Convulsion—Galantamine—Alzheimer's disease	0.000216	0.00196	CcSEcCtD
L-DOPA—Neuropathy peripheral—Rivastigmine—Alzheimer's disease	0.000216	0.00195	CcSEcCtD
L-DOPA—Myocardial infarction—Rivastigmine—Alzheimer's disease	0.000216	0.00195	CcSEcCtD
L-DOPA—Hypertension—Galantamine—Alzheimer's disease	0.000216	0.00195	CcSEcCtD
L-DOPA—Aminosalicylic Acid—MPO—Alzheimer's disease	0.000215	0.0641	CrCbGaD
L-DOPA—Urinary tract infection—Rivastigmine—Alzheimer's disease	0.000214	0.00194	CcSEcCtD
L-DOPA—Chest pain—Galantamine—Alzheimer's disease	0.000213	0.00193	CcSEcCtD
L-DOPA—Anxiety—Galantamine—Alzheimer's disease	0.000212	0.00192	CcSEcCtD
L-DOPA—Discomfort—Galantamine—Alzheimer's disease	0.00021	0.0019	CcSEcCtD
L-DOPA—Agranulocytosis—Memantine—Alzheimer's disease	0.00021	0.0019	CcSEcCtD
L-DOPA—Dry mouth—Galantamine—Alzheimer's disease	0.000208	0.00188	CcSEcCtD
L-DOPA—Confusional state—Galantamine—Alzheimer's disease	0.000205	0.00186	CcSEcCtD
L-DOPA—Haemoglobin—Memantine—Alzheimer's disease	0.000203	0.00184	CcSEcCtD
L-DOPA—Rhinitis—Memantine—Alzheimer's disease	0.000202	0.00183	CcSEcCtD
L-DOPA—Haemorrhage—Memantine—Alzheimer's disease	0.000202	0.00183	CcSEcCtD
L-DOPA—Hallucination—Memantine—Alzheimer's disease	0.000201	0.00182	CcSEcCtD
L-DOPA—Hypoaesthesia—Memantine—Alzheimer's disease	0.000201	0.00182	CcSEcCtD
L-DOPA—Shock—Galantamine—Alzheimer's disease	0.0002	0.00182	CcSEcCtD
L-DOPA—Thrombocytopenia—Galantamine—Alzheimer's disease	0.0002	0.00181	CcSEcCtD
L-DOPA—Urinary tract disorder—Memantine—Alzheimer's disease	0.000199	0.00181	CcSEcCtD
L-DOPA—Arrhythmia—Donepezil—Alzheimer's disease	0.000199	0.0018	CcSEcCtD
L-DOPA—Haemoglobin—Rivastigmine—Alzheimer's disease	0.000198	0.0018	CcSEcCtD
L-DOPA—Rhinitis—Rivastigmine—Alzheimer's disease	0.000198	0.00179	CcSEcCtD
L-DOPA—Urethral disorder—Memantine—Alzheimer's disease	0.000198	0.00179	CcSEcCtD
L-DOPA—Haemorrhage—Rivastigmine—Alzheimer's disease	0.000197	0.00179	CcSEcCtD
L-DOPA—Hyperhidrosis—Galantamine—Alzheimer's disease	0.000197	0.00178	CcSEcCtD
L-DOPA—Hallucination—Rivastigmine—Alzheimer's disease	0.000196	0.00178	CcSEcCtD
L-DOPA—Hypoaesthesia—Rivastigmine—Alzheimer's disease	0.000196	0.00178	CcSEcCtD
L-DOPA—Alopecia—Donepezil—Alzheimer's disease	0.000196	0.00178	CcSEcCtD
L-DOPA—Urinary tract disorder—Rivastigmine—Alzheimer's disease	0.000195	0.00177	CcSEcCtD
L-DOPA—Mental disorder—Donepezil—Alzheimer's disease	0.000195	0.00176	CcSEcCtD
L-DOPA—Anorexia—Galantamine—Alzheimer's disease	0.000194	0.00176	CcSEcCtD
L-DOPA—Urethral disorder—Rivastigmine—Alzheimer's disease	0.000194	0.00175	CcSEcCtD
L-DOPA—Flatulence—Donepezil—Alzheimer's disease	0.000191	0.00173	CcSEcCtD
L-DOPA—Hypotension—Galantamine—Alzheimer's disease	0.00019	0.00172	CcSEcCtD
L-DOPA—Tension—Donepezil—Alzheimer's disease	0.00019	0.00172	CcSEcCtD
L-DOPA—Dysgeusia—Donepezil—Alzheimer's disease	0.000189	0.00172	CcSEcCtD
L-DOPA—Nervousness—Donepezil—Alzheimer's disease	0.000188	0.0017	CcSEcCtD
L-DOPA—Flushing—Memantine—Alzheimer's disease	0.000187	0.0017	CcSEcCtD
L-DOPA—Back pain—Donepezil—Alzheimer's disease	0.000187	0.0017	CcSEcCtD
L-DOPA—Muscle spasms—Donepezil—Alzheimer's disease	0.000186	0.00169	CcSEcCtD
L-DOPA—Insomnia—Galantamine—Alzheimer's disease	0.000184	0.00167	CcSEcCtD
L-DOPA—Flushing—Rivastigmine—Alzheimer's disease	0.000183	0.00166	CcSEcCtD
L-DOPA—Paraesthesia—Galantamine—Alzheimer's disease	0.000183	0.00166	CcSEcCtD
L-DOPA—Vision blurred—Donepezil—Alzheimer's disease	0.000182	0.00165	CcSEcCtD
L-DOPA—Tremor—Donepezil—Alzheimer's disease	0.000181	0.00164	CcSEcCtD
L-DOPA—Somnolence—Galantamine—Alzheimer's disease	0.000181	0.00164	CcSEcCtD
L-DOPA—Arrhythmia—Memantine—Alzheimer's disease	0.00018	0.00163	CcSEcCtD
L-DOPA—DRD2—brain—Alzheimer's disease	0.00018	0.00412	CbGeAlD
L-DOPA—Ill-defined disorder—Donepezil—Alzheimer's disease	0.00018	0.00163	CcSEcCtD
L-DOPA—Dyspepsia—Galantamine—Alzheimer's disease	0.000179	0.00162	CcSEcCtD
L-DOPA—Anaemia—Donepezil—Alzheimer's disease	0.000179	0.00162	CcSEcCtD
L-DOPA—Alopecia—Memantine—Alzheimer's disease	0.000178	0.00162	CcSEcCtD
L-DOPA—Agitation—Donepezil—Alzheimer's disease	0.000178	0.00161	CcSEcCtD
L-DOPA—Decreased appetite—Galantamine—Alzheimer's disease	0.000177	0.0016	CcSEcCtD
L-DOPA—Mental disorder—Memantine—Alzheimer's disease	0.000177	0.0016	CcSEcCtD
L-DOPA—Arrhythmia—Rivastigmine—Alzheimer's disease	0.000176	0.0016	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.000176	0.00159	CcSEcCtD
L-DOPA—Fatigue—Galantamine—Alzheimer's disease	0.000176	0.00159	CcSEcCtD
L-DOPA—Malaise—Donepezil—Alzheimer's disease	0.000174	0.00158	CcSEcCtD
L-DOPA—Alopecia—Rivastigmine—Alzheimer's disease	0.000174	0.00158	CcSEcCtD
L-DOPA—Constipation—Galantamine—Alzheimer's disease	0.000174	0.00158	CcSEcCtD
L-DOPA—Syncope—Donepezil—Alzheimer's disease	0.000174	0.00157	CcSEcCtD
L-DOPA—Flatulence—Memantine—Alzheimer's disease	0.000173	0.00157	CcSEcCtD
L-DOPA—Mental disorder—Rivastigmine—Alzheimer's disease	0.000173	0.00157	CcSEcCtD
L-DOPA—Tension—Memantine—Alzheimer's disease	0.000172	0.00156	CcSEcCtD
L-DOPA—Dysgeusia—Memantine—Alzheimer's disease	0.000172	0.00156	CcSEcCtD
L-DOPA—Nervousness—Memantine—Alzheimer's disease	0.000171	0.00155	CcSEcCtD
L-DOPA—Loss of consciousness—Donepezil—Alzheimer's disease	0.00017	0.00154	CcSEcCtD
L-DOPA—Back pain—Memantine—Alzheimer's disease	0.00017	0.00154	CcSEcCtD
L-DOPA—Flatulence—Rivastigmine—Alzheimer's disease	0.000169	0.00153	CcSEcCtD
L-DOPA—Cough—Donepezil—Alzheimer's disease	0.000169	0.00153	CcSEcCtD
L-DOPA—Tension—Rivastigmine—Alzheimer's disease	0.000169	0.00153	CcSEcCtD
L-DOPA—Mesalazine—MPO—Alzheimer's disease	0.000168	0.0503	CrCbGaD
L-DOPA—Dysgeusia—Rivastigmine—Alzheimer's disease	0.000168	0.00152	CcSEcCtD
L-DOPA—Feeling abnormal—Galantamine—Alzheimer's disease	0.000168	0.00152	CcSEcCtD
L-DOPA—Convulsion—Donepezil—Alzheimer's disease	0.000168	0.00152	CcSEcCtD
L-DOPA—Hypertension—Donepezil—Alzheimer's disease	0.000167	0.00151	CcSEcCtD
L-DOPA—Nervousness—Rivastigmine—Alzheimer's disease	0.000167	0.00151	CcSEcCtD
L-DOPA—Gastrointestinal pain—Galantamine—Alzheimer's disease	0.000167	0.00151	CcSEcCtD
L-DOPA—Back pain—Rivastigmine—Alzheimer's disease	0.000166	0.00151	CcSEcCtD
L-DOPA—Vision blurred—Memantine—Alzheimer's disease	0.000166	0.0015	CcSEcCtD
L-DOPA—Muscle spasms—Rivastigmine—Alzheimer's disease	0.000165	0.0015	CcSEcCtD
L-DOPA—Chest pain—Donepezil—Alzheimer's disease	0.000165	0.00149	CcSEcCtD
L-DOPA—Tremor—Memantine—Alzheimer's disease	0.000165	0.00149	CcSEcCtD
L-DOPA—Anxiety—Donepezil—Alzheimer's disease	0.000164	0.00149	CcSEcCtD
L-DOPA—Ill-defined disorder—Memantine—Alzheimer's disease	0.000163	0.00148	CcSEcCtD
L-DOPA—Discomfort—Donepezil—Alzheimer's disease	0.000163	0.00147	CcSEcCtD
L-DOPA—Anaemia—Memantine—Alzheimer's disease	0.000162	0.00147	CcSEcCtD
L-DOPA—Vision blurred—Rivastigmine—Alzheimer's disease	0.000162	0.00147	CcSEcCtD
L-DOPA—Agitation—Memantine—Alzheimer's disease	0.000161	0.00146	CcSEcCtD
L-DOPA—Dry mouth—Donepezil—Alzheimer's disease	0.000161	0.00146	CcSEcCtD
L-DOPA—Abdominal pain—Galantamine—Alzheimer's disease	0.000161	0.00146	CcSEcCtD
L-DOPA—Tremor—Rivastigmine—Alzheimer's disease	0.000161	0.00146	CcSEcCtD
L-DOPA—Ill-defined disorder—Rivastigmine—Alzheimer's disease	0.000159	0.00144	CcSEcCtD
L-DOPA—Confusional state—Donepezil—Alzheimer's disease	0.000159	0.00144	CcSEcCtD
L-DOPA—Anaemia—Rivastigmine—Alzheimer's disease	0.000159	0.00144	CcSEcCtD
L-DOPA—Malaise—Memantine—Alzheimer's disease	0.000158	0.00144	CcSEcCtD
L-DOPA—Agitation—Rivastigmine—Alzheimer's disease	0.000158	0.00143	CcSEcCtD
L-DOPA—Oedema—Donepezil—Alzheimer's disease	0.000158	0.00143	CcSEcCtD
L-DOPA—Syncope—Memantine—Alzheimer's disease	0.000158	0.00143	CcSEcCtD
L-DOPA—Leukopenia—Memantine—Alzheimer's disease	0.000157	0.00142	CcSEcCtD
L-DOPA—Shock—Donepezil—Alzheimer's disease	0.000155	0.00141	CcSEcCtD
L-DOPA—Palpitations—Memantine—Alzheimer's disease	0.000155	0.00141	CcSEcCtD
L-DOPA—Malaise—Rivastigmine—Alzheimer's disease	0.000155	0.0014	CcSEcCtD
L-DOPA—Thrombocytopenia—Donepezil—Alzheimer's disease	0.000155	0.0014	CcSEcCtD
L-DOPA—Loss of consciousness—Memantine—Alzheimer's disease	0.000154	0.0014	CcSEcCtD
L-DOPA—Syncope—Rivastigmine—Alzheimer's disease	0.000154	0.0014	CcSEcCtD
L-DOPA—Cough—Memantine—Alzheimer's disease	0.000153	0.00139	CcSEcCtD
L-DOPA—Hyperhidrosis—Donepezil—Alzheimer's disease	0.000153	0.00138	CcSEcCtD
L-DOPA—Convulsion—Memantine—Alzheimer's disease	0.000152	0.00138	CcSEcCtD
L-DOPA—Palpitations—Rivastigmine—Alzheimer's disease	0.000152	0.00138	CcSEcCtD
L-DOPA—Hypertension—Memantine—Alzheimer's disease	0.000152	0.00137	CcSEcCtD
L-DOPA—Loss of consciousness—Rivastigmine—Alzheimer's disease	0.000151	0.00137	CcSEcCtD
L-DOPA—Anorexia—Donepezil—Alzheimer's disease	0.000151	0.00136	CcSEcCtD
L-DOPA—Hypersensitivity—Galantamine—Alzheimer's disease	0.00015	0.00136	CcSEcCtD
L-DOPA—Cough—Rivastigmine—Alzheimer's disease	0.00015	0.00136	CcSEcCtD
L-DOPA—Chest pain—Memantine—Alzheimer's disease	0.00015	0.00135	CcSEcCtD
L-DOPA—Mesalazine—PPARG—Alzheimer's disease	0.00015	0.0447	CrCbGaD
L-DOPA—Anxiety—Memantine—Alzheimer's disease	0.000149	0.00135	CcSEcCtD
L-DOPA—Convulsion—Rivastigmine—Alzheimer's disease	0.000149	0.00135	CcSEcCtD
L-DOPA—Hypertension—Rivastigmine—Alzheimer's disease	0.000148	0.00134	CcSEcCtD
L-DOPA—Discomfort—Memantine—Alzheimer's disease	0.000148	0.00134	CcSEcCtD
L-DOPA—Hypotension—Donepezil—Alzheimer's disease	0.000148	0.00134	CcSEcCtD
L-DOPA—Chest pain—Rivastigmine—Alzheimer's disease	0.000146	0.00133	CcSEcCtD
L-DOPA—Dry mouth—Memantine—Alzheimer's disease	0.000146	0.00132	CcSEcCtD
L-DOPA—Asthenia—Galantamine—Alzheimer's disease	0.000146	0.00132	CcSEcCtD
L-DOPA—Anxiety—Rivastigmine—Alzheimer's disease	0.000146	0.00132	CcSEcCtD
L-DOPA—Confusional state—Memantine—Alzheimer's disease	0.000145	0.00131	CcSEcCtD
L-DOPA—Discomfort—Rivastigmine—Alzheimer's disease	0.000145	0.00131	CcSEcCtD
L-DOPA—Oedema—Memantine—Alzheimer's disease	0.000143	0.0013	CcSEcCtD
L-DOPA—Dry mouth—Rivastigmine—Alzheimer's disease	0.000143	0.0013	CcSEcCtD
L-DOPA—Insomnia—Donepezil—Alzheimer's disease	0.000143	0.00129	CcSEcCtD
L-DOPA—Paraesthesia—Donepezil—Alzheimer's disease	0.000142	0.00128	CcSEcCtD
L-DOPA—Confusional state—Rivastigmine—Alzheimer's disease	0.000141	0.00128	CcSEcCtD
L-DOPA—CYP2D6—nervous system—Alzheimer's disease	0.000141	0.00324	CbGeAlD
L-DOPA—Shock—Memantine—Alzheimer's disease	0.000141	0.00128	CcSEcCtD
L-DOPA—Dyspnoea—Donepezil—Alzheimer's disease	0.000141	0.00128	CcSEcCtD
L-DOPA—Aminosalicylic Acid—PTGS1—Alzheimer's disease	0.000141	0.0421	CrCbGaD
L-DOPA—Somnolence—Donepezil—Alzheimer's disease	0.00014	0.00127	CcSEcCtD
L-DOPA—Thrombocytopenia—Memantine—Alzheimer's disease	0.00014	0.00127	CcSEcCtD
L-DOPA—Oedema—Rivastigmine—Alzheimer's disease	0.00014	0.00127	CcSEcCtD
L-DOPA—Dopamine—MAOB—Alzheimer's disease	0.00014	0.0417	CrCbGaD
L-DOPA—Diarrhoea—Galantamine—Alzheimer's disease	0.000139	0.00126	CcSEcCtD
L-DOPA—Dyspepsia—Donepezil—Alzheimer's disease	0.000139	0.00126	CcSEcCtD
L-DOPA—Hyperhidrosis—Memantine—Alzheimer's disease	0.000139	0.00126	CcSEcCtD
L-DOPA—Shock—Rivastigmine—Alzheimer's disease	0.000138	0.00125	CcSEcCtD
L-DOPA—Thrombocytopenia—Rivastigmine—Alzheimer's disease	0.000137	0.00124	CcSEcCtD
L-DOPA—Decreased appetite—Donepezil—Alzheimer's disease	0.000137	0.00124	CcSEcCtD
L-DOPA—Anorexia—Memantine—Alzheimer's disease	0.000137	0.00124	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Donepezil—Alzheimer's disease	0.000136	0.00123	CcSEcCtD
L-DOPA—Fatigue—Donepezil—Alzheimer's disease	0.000136	0.00123	CcSEcCtD
L-DOPA—CYP2D6—central nervous system—Alzheimer's disease	0.000136	0.00312	CbGeAlD
L-DOPA—Hyperhidrosis—Rivastigmine—Alzheimer's disease	0.000136	0.00123	CcSEcCtD
L-DOPA—Pain—Donepezil—Alzheimer's disease	0.000135	0.00122	CcSEcCtD
L-DOPA—Constipation—Donepezil—Alzheimer's disease	0.000135	0.00122	CcSEcCtD
L-DOPA—Dizziness—Galantamine—Alzheimer's disease	0.000135	0.00122	CcSEcCtD
L-DOPA—Hypotension—Memantine—Alzheimer's disease	0.000134	0.00121	CcSEcCtD
L-DOPA—Anorexia—Rivastigmine—Alzheimer's disease	0.000134	0.00121	CcSEcCtD
L-DOPA—CYP2D6—cerebellum—Alzheimer's disease	0.000133	0.00305	CbGeAlD
L-DOPA—Hypotension—Rivastigmine—Alzheimer's disease	0.000131	0.00119	CcSEcCtD
L-DOPA—Feeling abnormal—Donepezil—Alzheimer's disease	0.00013	0.00118	CcSEcCtD
L-DOPA—Insomnia—Memantine—Alzheimer's disease	0.00013	0.00117	CcSEcCtD
L-DOPA—Vomiting—Galantamine—Alzheimer's disease	0.00013	0.00117	CcSEcCtD
L-DOPA—Gastrointestinal pain—Donepezil—Alzheimer's disease	0.000129	0.00117	CcSEcCtD
L-DOPA—Paraesthesia—Memantine—Alzheimer's disease	0.000129	0.00117	CcSEcCtD
L-DOPA—Rash—Galantamine—Alzheimer's disease	0.000128	0.00116	CcSEcCtD
L-DOPA—Dermatitis—Galantamine—Alzheimer's disease	0.000128	0.00116	CcSEcCtD
L-DOPA—Dyspnoea—Memantine—Alzheimer's disease	0.000128	0.00116	CcSEcCtD
L-DOPA—Headache—Galantamine—Alzheimer's disease	0.000128	0.00116	CcSEcCtD
L-DOPA—Somnolence—Memantine—Alzheimer's disease	0.000127	0.00115	CcSEcCtD
L-DOPA—Insomnia—Rivastigmine—Alzheimer's disease	0.000127	0.00115	CcSEcCtD
L-DOPA—Dyspepsia—Memantine—Alzheimer's disease	0.000126	0.00114	CcSEcCtD
L-DOPA—Paraesthesia—Rivastigmine—Alzheimer's disease	0.000126	0.00114	CcSEcCtD
L-DOPA—Urticaria—Donepezil—Alzheimer's disease	0.000125	0.00114	CcSEcCtD
L-DOPA—Dyspnoea—Rivastigmine—Alzheimer's disease	0.000125	0.00113	CcSEcCtD
L-DOPA—Abdominal pain—Donepezil—Alzheimer's disease	0.000125	0.00113	CcSEcCtD
L-DOPA—Somnolence—Rivastigmine—Alzheimer's disease	0.000125	0.00113	CcSEcCtD
L-DOPA—Decreased appetite—Memantine—Alzheimer's disease	0.000125	0.00113	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Memantine—Alzheimer's disease	0.000124	0.00112	CcSEcCtD
L-DOPA—Fatigue—Memantine—Alzheimer's disease	0.000124	0.00112	CcSEcCtD
L-DOPA—Dyspepsia—Rivastigmine—Alzheimer's disease	0.000123	0.00112	CcSEcCtD
L-DOPA—Pain—Memantine—Alzheimer's disease	0.000123	0.00111	CcSEcCtD
L-DOPA—Constipation—Memantine—Alzheimer's disease	0.000123	0.00111	CcSEcCtD
L-DOPA—Decreased appetite—Rivastigmine—Alzheimer's disease	0.000122	0.0011	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	0.000121	0.0011	CcSEcCtD
L-DOPA—Nausea—Galantamine—Alzheimer's disease	0.000121	0.0011	CcSEcCtD
L-DOPA—Fatigue—Rivastigmine—Alzheimer's disease	0.000121	0.0011	CcSEcCtD
L-DOPA—Constipation—Rivastigmine—Alzheimer's disease	0.00012	0.00109	CcSEcCtD
L-DOPA—Pain—Rivastigmine—Alzheimer's disease	0.00012	0.00109	CcSEcCtD
L-DOPA—Feeling abnormal—Memantine—Alzheimer's disease	0.000118	0.00107	CcSEcCtD
L-DOPA—Gastrointestinal pain—Memantine—Alzheimer's disease	0.000117	0.00106	CcSEcCtD
L-DOPA—Hypersensitivity—Donepezil—Alzheimer's disease	0.000116	0.00105	CcSEcCtD
L-DOPA—Feeling abnormal—Rivastigmine—Alzheimer's disease	0.000116	0.00105	CcSEcCtD
L-DOPA—Gastrointestinal pain—Rivastigmine—Alzheimer's disease	0.000115	0.00104	CcSEcCtD
L-DOPA—Urticaria—Memantine—Alzheimer's disease	0.000114	0.00103	CcSEcCtD
L-DOPA—Abdominal pain—Memantine—Alzheimer's disease	0.000113	0.00103	CcSEcCtD
L-DOPA—Asthenia—Donepezil—Alzheimer's disease	0.000113	0.00103	CcSEcCtD
L-DOPA—Pruritus—Donepezil—Alzheimer's disease	0.000112	0.00101	CcSEcCtD
L-DOPA—Urticaria—Rivastigmine—Alzheimer's disease	0.000111	0.00101	CcSEcCtD
L-DOPA—Abdominal pain—Rivastigmine—Alzheimer's disease	0.000111	0.001	CcSEcCtD
L-DOPA—Mesalazine—PTGS1—Alzheimer's disease	0.00011	0.033	CrCbGaD
L-DOPA—Diarrhoea—Donepezil—Alzheimer's disease	0.000108	0.000979	CcSEcCtD
L-DOPA—CYP2D6—brain—Alzheimer's disease	0.000108	0.00248	CbGeAlD
L-DOPA—Hypersensitivity—Memantine—Alzheimer's disease	0.000106	0.000957	CcSEcCtD
L-DOPA—Dizziness—Donepezil—Alzheimer's disease	0.000104	0.000946	CcSEcCtD
L-DOPA—Hypersensitivity—Rivastigmine—Alzheimer's disease	0.000103	0.000936	CcSEcCtD
L-DOPA—Asthenia—Memantine—Alzheimer's disease	0.000103	0.000932	CcSEcCtD
L-DOPA—Pruritus—Memantine—Alzheimer's disease	0.000101	0.000919	CcSEcCtD
L-DOPA—Asthenia—Rivastigmine—Alzheimer's disease	0.000101	0.000912	CcSEcCtD
L-DOPA—Vomiting—Donepezil—Alzheimer's disease	0.0001	0.000909	CcSEcCtD
L-DOPA—Rash—Donepezil—Alzheimer's disease	9.96e-05	0.000902	CcSEcCtD
L-DOPA—Dermatitis—Donepezil—Alzheimer's disease	9.95e-05	0.000901	CcSEcCtD
L-DOPA—Pruritus—Rivastigmine—Alzheimer's disease	9.92e-05	0.000899	CcSEcCtD
L-DOPA—Headache—Donepezil—Alzheimer's disease	9.89e-05	0.000896	CcSEcCtD
L-DOPA—Diarrhoea—Memantine—Alzheimer's disease	9.81e-05	0.000889	CcSEcCtD
L-DOPA—Diarrhoea—Rivastigmine—Alzheimer's disease	9.6e-05	0.000869	CcSEcCtD
L-DOPA—Dizziness—Memantine—Alzheimer's disease	9.48e-05	0.000859	CcSEcCtD
L-DOPA—Nausea—Donepezil—Alzheimer's disease	9.38e-05	0.00085	CcSEcCtD
L-DOPA—Dizziness—Rivastigmine—Alzheimer's disease	9.28e-05	0.00084	CcSEcCtD
L-DOPA—Vomiting—Memantine—Alzheimer's disease	9.12e-05	0.000826	CcSEcCtD
L-DOPA—Rash—Memantine—Alzheimer's disease	9.04e-05	0.000819	CcSEcCtD
L-DOPA—Dermatitis—Memantine—Alzheimer's disease	9.03e-05	0.000818	CcSEcCtD
L-DOPA—Headache—Memantine—Alzheimer's disease	8.98e-05	0.000814	CcSEcCtD
L-DOPA—Vomiting—Rivastigmine—Alzheimer's disease	8.92e-05	0.000808	CcSEcCtD
L-DOPA—Rash—Rivastigmine—Alzheimer's disease	8.84e-05	0.000801	CcSEcCtD
L-DOPA—Dermatitis—Rivastigmine—Alzheimer's disease	8.84e-05	0.0008	CcSEcCtD
L-DOPA—Headache—Rivastigmine—Alzheimer's disease	8.79e-05	0.000796	CcSEcCtD
L-DOPA—Nausea—Memantine—Alzheimer's disease	8.52e-05	0.000771	CcSEcCtD
L-DOPA—Nausea—Rivastigmine—Alzheimer's disease	8.33e-05	0.000755	CcSEcCtD
L-DOPA—Aminosalicylic Acid—PTGS2—Alzheimer's disease	8.05e-05	0.024	CrCbGaD
L-DOPA—Epinephrine—TNF—Alzheimer's disease	7.65e-05	0.0229	CrCbGaD
L-DOPA—Mesalazine—PTGS2—Alzheimer's disease	6.31e-05	0.0189	CrCbGaD
L-DOPA—Dopamine—SLC6A4—Alzheimer's disease	6.31e-05	0.0189	CrCbGaD
L-DOPA—Dopamine—CYP2D6—Alzheimer's disease	4.44e-05	0.0133	CrCbGaD
L-DOPA—DRD5—Signaling Pathways—LPL—Alzheimer's disease	7.56e-06	0.000145	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NPS—Alzheimer's disease	7.53e-06	0.000144	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MEF2C—Alzheimer's disease	7.49e-06	0.000144	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PPP3CA—Alzheimer's disease	7.49e-06	0.000144	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—F2—Alzheimer's disease	7.47e-06	0.000143	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NPS—Alzheimer's disease	7.43e-06	0.000142	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—F2—Alzheimer's disease	7.4e-06	0.000142	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PPP3CA—Alzheimer's disease	7.39e-06	0.000142	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTK2B—Alzheimer's disease	7.38e-06	0.000141	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PRKCG—Alzheimer's disease	7.35e-06	0.000141	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PLCB1—Alzheimer's disease	7.34e-06	0.000141	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—IL6—Alzheimer's disease	7.33e-06	0.00014	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—F2—Alzheimer's disease	7.3e-06	0.00014	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTK2B—Alzheimer's disease	7.28e-06	0.00014	CbGpPWpGaD
L-DOPA—DDC—Metabolism—NOS3—Alzheimer's disease	7.23e-06	0.000138	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NTRK2—Alzheimer's disease	7.18e-06	0.000138	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GAB2—Alzheimer's disease	7.18e-06	0.000138	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SST—Alzheimer's disease	7.18e-06	0.000138	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NGF—Alzheimer's disease	7.16e-06	0.000137	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CALM1—Alzheimer's disease	7.15e-06	0.000137	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GSK3A—Alzheimer's disease	7.12e-06	0.000136	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SST—Alzheimer's disease	7.09e-06	0.000136	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NTRK2—Alzheimer's disease	7.09e-06	0.000136	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GAB2—Alzheimer's disease	7.09e-06	0.000136	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CALM1—Alzheimer's disease	7.06e-06	0.000135	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GSK3A—Alzheimer's disease	7.02e-06	0.000135	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APP—Alzheimer's disease	7e-06	0.000134	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—A2M—Alzheimer's disease	6.97e-06	0.000134	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCR5—Alzheimer's disease	6.97e-06	0.000133	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APP—Alzheimer's disease	6.91e-06	0.000132	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PRKCG—Alzheimer's disease	6.87e-06	0.000132	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NGFR—Alzheimer's disease	6.84e-06	0.000131	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HTR2A—Alzheimer's disease	6.82e-06	0.000131	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CREB1—Alzheimer's disease	6.8e-06	0.00013	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PSEN2—Alzheimer's disease	6.75e-06	0.000129	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—F2—Alzheimer's disease	6.72e-06	0.000129	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ADAM10—Alzheimer's disease	6.69e-06	0.000128	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CCL2—Alzheimer's disease	6.65e-06	0.000127	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—F2—Alzheimer's disease	6.63e-06	0.000127	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PTGS2—Alzheimer's disease	6.61e-06	0.000127	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PLCB1—Alzheimer's disease	6.6e-06	0.000127	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PLCB1—Alzheimer's disease	6.52e-06	0.000125	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CCR5—Alzheimer's disease	6.51e-06	0.000125	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—HTR2A—Alzheimer's disease	6.37e-06	0.000122	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CALM1—Alzheimer's disease	6.36e-06	0.000122	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—LEP—Alzheimer's disease	6.34e-06	0.000121	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—APOE—Alzheimer's disease	6.34e-06	0.000121	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—S100B—Alzheimer's disease	6.32e-06	0.000121	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CAV1—Alzheimer's disease	6.28e-06	0.00012	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PRKCG—Alzheimer's disease	6.24e-06	0.00012	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NPY—Alzheimer's disease	6.21e-06	0.000119	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IAPP—Alzheimer's disease	6.18e-06	0.000118	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NGFR—Alzheimer's disease	6.16e-06	0.000118	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CREB1—Alzheimer's disease	6.12e-06	0.000117	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NGFR—Alzheimer's disease	6.08e-06	0.000116	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ESR1—Alzheimer's disease	6.05e-06	0.000116	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CREB1—Alzheimer's disease	6.04e-06	0.000116	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IGF2—Alzheimer's disease	6.02e-06	0.000115	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ADAM10—Alzheimer's disease	6.02e-06	0.000115	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CRH—Alzheimer's disease	6e-06	0.000115	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CCL2—Alzheimer's disease	5.99e-06	0.000115	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—F2—Alzheimer's disease	5.98e-06	0.000114	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ADAM10—Alzheimer's disease	5.94e-06	0.000114	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCR5—Alzheimer's disease	5.92e-06	0.000113	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CCL2—Alzheimer's disease	5.91e-06	0.000113	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NOTCH1—Alzheimer's disease	5.85e-06	0.000112	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IGF1R—Alzheimer's disease	5.82e-06	0.000111	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HTR2A—Alzheimer's disease	5.79e-06	0.000111	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—S100B—Alzheimer's disease	5.69e-06	0.000109	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NPS—Alzheimer's disease	5.68e-06	0.000109	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PPP3CA—Alzheimer's disease	5.66e-06	0.000108	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—S100B—Alzheimer's disease	5.62e-06	0.000108	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—F2—Alzheimer's disease	5.59e-06	0.000107	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—LPL—Alzheimer's disease	5.58e-06	0.000107	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTK2B—Alzheimer's disease	5.57e-06	0.000107	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MEF2C—Alzheimer's disease	5.53e-06	0.000106	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—GSK3B—Alzheimer's disease	5.49e-06	0.000105	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TPI1—Alzheimer's disease	5.46e-06	0.000105	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CHAT—Alzheimer's disease	5.46e-06	0.000105	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CREB1—Alzheimer's disease	5.44e-06	0.000104	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PRKCG—Alzheimer's disease	5.43e-06	0.000104	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SST—Alzheimer's disease	5.42e-06	0.000104	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GAB2—Alzheimer's disease	5.42e-06	0.000104	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NTRK2—Alzheimer's disease	5.42e-06	0.000104	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF2—Alzheimer's disease	5.42e-06	0.000104	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—INS—Alzheimer's disease	5.41e-06	0.000104	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CALM1—Alzheimer's disease	5.4e-06	0.000103	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GSK3A—Alzheimer's disease	5.38e-06	0.000103	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF2—Alzheimer's disease	5.35e-06	0.000102	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCL2—Alzheimer's disease	5.33e-06	0.000102	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NGF—Alzheimer's disease	5.28e-06	0.000101	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APP—Alzheimer's disease	5.28e-06	0.000101	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF1R—Alzheimer's disease	5.24e-06	0.0001	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IGF1—Alzheimer's disease	5.24e-06	0.0001	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—MAOB—Alzheimer's disease	5.23e-06	0.0001	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF1R—Alzheimer's disease	5.17e-06	9.9e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCR5—Alzheimer's disease	5.14e-06	9.85e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—F2—Alzheimer's disease	5.07e-06	9.72e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GAPDH—Alzheimer's disease	5.04e-06	9.65e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HTR2A—Alzheimer's disease	5.03e-06	9.64e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—LPL—Alzheimer's disease	5.02e-06	9.62e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PLCB1—Alzheimer's disease	4.99e-06	9.55e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MEF2C—Alzheimer's disease	4.98e-06	9.54e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—LPL—Alzheimer's disease	4.96e-06	9.49e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MEF2C—Alzheimer's disease	4.91e-06	9.41e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PRKCG—Alzheimer's disease	4.88e-06	9.36e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—A2M—Alzheimer's disease	4.86e-06	9.32e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PRKCG—Alzheimer's disease	4.82e-06	9.23e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NGF—Alzheimer's disease	4.76e-06	9.11e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NOS3—Alzheimer's disease	4.75e-06	9.09e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NGF—Alzheimer's disease	4.69e-06	8.99e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CALM1—Alzheimer's disease	4.69e-06	8.99e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—LEP—Alzheimer's disease	4.68e-06	8.96e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APOE—Alzheimer's disease	4.68e-06	8.96e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NGFR—Alzheimer's disease	4.65e-06	8.91e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CAV1—Alzheimer's disease	4.63e-06	8.88e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCR5—Alzheimer's disease	4.63e-06	8.87e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CREB1—Alzheimer's disease	4.62e-06	8.86e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCR5—Alzheimer's disease	4.57e-06	8.75e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ADAM10—Alzheimer's disease	4.54e-06	8.7e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HTR2A—Alzheimer's disease	4.53e-06	8.68e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCL2—Alzheimer's disease	4.52e-06	8.66e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HTR2A—Alzheimer's disease	4.47e-06	8.56e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ESR1—Alzheimer's disease	4.47e-06	8.55e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—F2—Alzheimer's disease	4.41e-06	8.45e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NOTCH1—Alzheimer's disease	4.32e-06	8.27e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—S100B—Alzheimer's disease	4.3e-06	8.23e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ACHE—Alzheimer's disease	4.23e-06	8.11e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CALM1—Alzheimer's disease	4.23e-06	8.09e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—LEP—Alzheimer's disease	4.21e-06	8.07e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APOE—Alzheimer's disease	4.21e-06	8.07e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—INPP5D—Alzheimer's disease	4.18e-06	8.01e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CAV1—Alzheimer's disease	4.17e-06	7.99e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CALM1—Alzheimer's disease	4.17e-06	7.99e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—LEP—Alzheimer's disease	4.15e-06	7.96e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APOE—Alzheimer's disease	4.15e-06	7.96e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CAV1—Alzheimer's disease	4.12e-06	7.88e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF2—Alzheimer's disease	4.09e-06	7.84e-05	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—AKT1—Alzheimer's disease	4.07e-06	7.79e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GSK3B—Alzheimer's disease	4.05e-06	7.76e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CASP3—Alzheimer's disease	4.03e-06	7.72e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ESR1—Alzheimer's disease	4.02e-06	7.7e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CREB1—Alzheimer's disease	4.02e-06	7.7e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL6—Alzheimer's disease	4e-06	7.67e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—INS—Alzheimer's disease	4e-06	7.65e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—F2—Alzheimer's disease	3.97e-06	7.61e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ESR1—Alzheimer's disease	3.97e-06	7.6e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ENO1—Alzheimer's disease	3.97e-06	7.6e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS1—Alzheimer's disease	3.97e-06	7.6e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF1R—Alzheimer's disease	3.96e-06	7.58e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCL2—Alzheimer's disease	3.93e-06	7.53e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—F2—Alzheimer's disease	3.92e-06	7.5e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOTCH1—Alzheimer's disease	3.89e-06	7.44e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IGF1—Alzheimer's disease	3.86e-06	7.4e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOTCH1—Alzheimer's disease	3.83e-06	7.34e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—LPL—Alzheimer's disease	3.79e-06	7.26e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MEF2C—Alzheimer's disease	3.76e-06	7.2e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK8—Alzheimer's disease	3.7e-06	7.1e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AKT1—Alzheimer's disease	3.69e-06	7.08e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PRKCG—Alzheimer's disease	3.69e-06	7.06e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—BCHE—Alzheimer's disease	3.69e-06	7.06e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GSK3B—Alzheimer's disease	3.65e-06	6.99e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CREB1—Alzheimer's disease	3.62e-06	6.93e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GSK3B—Alzheimer's disease	3.6e-06	6.89e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—INS—Alzheimer's disease	3.6e-06	6.89e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NGF—Alzheimer's disease	3.59e-06	6.88e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CREB1—Alzheimer's disease	3.57e-06	6.84e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—INS—Alzheimer's disease	3.55e-06	6.8e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCL2—Alzheimer's disease	3.54e-06	6.78e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NOS3—Alzheimer's disease	3.5e-06	6.71e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCR5—Alzheimer's disease	3.49e-06	6.69e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCL2—Alzheimer's disease	3.49e-06	6.69e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF1—Alzheimer's disease	3.48e-06	6.66e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PLCB1—Alzheimer's disease	3.48e-06	6.66e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF1—Alzheimer's disease	3.43e-06	6.58e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—Alzheimer's disease	3.42e-06	6.55e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HTR2A—Alzheimer's disease	3.42e-06	6.55e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ABCA1—Alzheimer's disease	3.37e-06	6.46e-05	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AKT1—Alzheimer's disease	3.32e-06	6.36e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CALM1—Alzheimer's disease	3.19e-06	6.11e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—LEP—Alzheimer's disease	3.18e-06	6.09e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOE—Alzheimer's disease	3.18e-06	6.09e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOS3—Alzheimer's disease	3.15e-06	6.04e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CAV1—Alzheimer's disease	3.15e-06	6.03e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TGFB1—Alzheimer's disease	3.14e-06	6.01e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOS3—Alzheimer's disease	3.11e-06	5.96e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ESR1—Alzheimer's disease	3.04e-06	5.81e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AKT1—Alzheimer's disease	3e-06	5.75e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—F2—Alzheimer's disease	3e-06	5.74e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CASP3—Alzheimer's disease	2.97e-06	5.7e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL6—Alzheimer's disease	2.96e-06	5.66e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOTCH1—Alzheimer's disease	2.93e-06	5.62e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPARGC1A—Alzheimer's disease	2.91e-06	5.57e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HMOX1—Alzheimer's disease	2.89e-06	5.54e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GSK3B—Alzheimer's disease	2.75e-06	5.27e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK8—Alzheimer's disease	2.73e-06	5.24e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CREB1—Alzheimer's disease	2.73e-06	5.23e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AKT1—Alzheimer's disease	2.73e-06	5.22e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—INS—Alzheimer's disease	2.72e-06	5.2e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AKT1—Alzheimer's disease	2.7e-06	5.18e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CASP3—Alzheimer's disease	2.68e-06	5.13e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL2—Alzheimer's disease	2.67e-06	5.12e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AKT1—Alzheimer's disease	2.67e-06	5.11e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6—Alzheimer's disease	2.66e-06	5.1e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—LPL—Alzheimer's disease	2.65e-06	5.07e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CASP3—Alzheimer's disease	2.64e-06	5.06e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF1—Alzheimer's disease	2.63e-06	5.03e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6—Alzheimer's disease	2.63e-06	5.03e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—Alzheimer's disease	2.58e-06	4.95e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—Alzheimer's disease	2.52e-06	4.84e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK8—Alzheimer's disease	2.46e-06	4.71e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AKT1—Alzheimer's disease	2.45e-06	4.7e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK8—Alzheimer's disease	2.43e-06	4.65e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AKT1—Alzheimer's disease	2.42e-06	4.64e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—MTHFR—Alzheimer's disease	2.38e-06	4.56e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOS3—Alzheimer's disease	2.38e-06	4.56e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6—Alzheimer's disease	2.37e-06	4.53e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TGFB1—Alzheimer's disease	2.32e-06	4.44e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—Alzheimer's disease	2.27e-06	4.35e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—Alzheimer's disease	2.24e-06	4.3e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CALM1—Alzheimer's disease	2.23e-06	4.26e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOE—Alzheimer's disease	2.22e-06	4.25e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CAV1—Alzheimer's disease	2.2e-06	4.21e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKT1—Alzheimer's disease	2.18e-06	4.18e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TGFB1—Alzheimer's disease	2.09e-06	4e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TGFB1—Alzheimer's disease	2.06e-06	3.94e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT1—Alzheimer's disease	2.04e-06	3.91e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CASP3—Alzheimer's disease	2.02e-06	3.87e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6—Alzheimer's disease	2.01e-06	3.85e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPARG—Alzheimer's disease	1.93e-06	3.7e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—Alzheimer's disease	1.91e-06	3.65e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—INS—Alzheimer's disease	1.89e-06	3.63e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK8—Alzheimer's disease	1.86e-06	3.56e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT1—Alzheimer's disease	1.85e-06	3.55e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6—Alzheimer's disease	1.75e-06	3.34e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—Alzheimer's disease	1.72e-06	3.29e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—Alzheimer's disease	1.72e-06	3.29e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—Alzheimer's disease	1.69e-06	3.25e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NOS3—Alzheimer's disease	1.66e-06	3.18e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT1—Alzheimer's disease	1.61e-06	3.09e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TGFB1—Alzheimer's disease	1.57e-06	3.02e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6—Alzheimer's disease	1.57e-06	3.01e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6—Alzheimer's disease	1.55e-06	2.97e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—Alzheimer's disease	1.52e-06	2.91e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT1—Alzheimer's disease	1.45e-06	2.78e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT1—Alzheimer's disease	1.43e-06	2.74e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—Alzheimer's disease	1.3e-06	2.48e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6—Alzheimer's disease	1.19e-06	2.27e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT1—Alzheimer's disease	1.09e-06	2.1e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKT1—Alzheimer's disease	7.64e-07	1.46e-05	CbGpPWpGaD
